FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990763313> ?p ?o ?g. }

• W2990763313 abstract "Introduction and Background: Before the European market approval, mepolizumab was made available in France as part of an early access program called Temporary Authorization for Utilization (ATU) for the treatment of severe eosinophilic asthma (SEA). GSK conducted a retrospective study to collect follow-up data in patients initiated within this program. Aims and Objectives: The aim of this study is to describe the patients’ baseline characteristics and outcomes (maximal follow-up of 24 months) and to generate the first set of real life data with mepolizumab in France. Methods: Data were collected from 147 patients out of the 183 initiated with mepolizumab within ATU, using medical records. Results: Patients had SEA (mean eosinophil count 719.5), received high doses of inhaled corticosteroids, associated with a long acting beta 2 agonist in 89.6%. The mean exacerbation rate in the previous year was 5.9 (4.4). Most patients (93%) were on maintenance oral corticosteroids (OCS), at a mean dose of 20.4 mg/day at treatment initiation. The annual exacerbation rate was reduced by 83%, and 90% at 12 and 24 months respectively. The reduction of the mean daily oral OCS dose was 60% at 12 months, and 71% at 24 months, 74% patients being OCS free at 24 months. Mean ACT score was improved from 10.2 at baseline to 18.7 at 24 months, predicted FEV1 was improved from 62% to 71%, after 24 months follow-up. Safety was consistent to that observed in clinical trials. Conclusions: Data from mepolizumab-treated SEA patients in the French early access program confirm mepolizumab effectiveness in real-life setting, with important exacerbation rate reduction and OCS sparing. Funding: GSK [207943]" @default.
• W2990763313 created "2019-12-05" @default.
• W2990763313 creator A5006590661 @default.
• W2990763313 creator A5038824744 @default.
• W2990763313 creator A5048057602 @default.
• W2990763313 creator A5052478392 @default.
• W2990763313 creator A5053600555 @default.
• W2990763313 creator A5061729379 @default.
• W2990763313 creator A5076809475 @default.
• W2990763313 creator A5076829016 @default.
• W2990763313 creator A5082059107 @default.
• W2990763313 creator A5086312824 @default.
• W2990763313 date "2019-09-28" @default.
• W2990763313 modified "2023-10-16" @default.
• W2990763313 title "Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma" @default.
• W2990763313 doi "https://doi.org/10.1183/13993003.congress-2019.pa1654" @default.
• W2990763313 hasPublicationYear "2019" @default.
• W2990763313 type Work @default.
• W2990763313 sameAs 2990763313 @default.
• W2990763313 citedByCount "2" @default.
• W2990763313 countsByYear W29907633132020 @default.
• W2990763313 countsByYear W29907633132021 @default.
• W2990763313 crossrefType "proceedings-article" @default.
• W2990763313 hasAuthorship W2990763313A5006590661 @default.
• W2990763313 hasAuthorship W2990763313A5038824744 @default.
• W2990763313 hasAuthorship W2990763313A5048057602 @default.
• W2990763313 hasAuthorship W2990763313A5052478392 @default.
• W2990763313 hasAuthorship W2990763313A5053600555 @default.
• W2990763313 hasAuthorship W2990763313A5061729379 @default.
• W2990763313 hasAuthorship W2990763313A5076809475 @default.
• W2990763313 hasAuthorship W2990763313A5076829016 @default.
• W2990763313 hasAuthorship W2990763313A5082059107 @default.
• W2990763313 hasAuthorship W2990763313A5086312824 @default.
• W2990763313 hasConcept C142724271 @default.
• W2990763313 hasConcept C203014093 @default.
• W2990763313 hasConcept C2776042228 @default.
• W2990763313 hasConcept C2777037409 @default.
• W2990763313 hasConcept C2777832160 @default.
• W2990763313 hasConcept C2779758542 @default.
• W2990763313 hasConcept C71924100 @default.
• W2990763313 hasConceptScore W2990763313C142724271 @default.
• W2990763313 hasConceptScore W2990763313C203014093 @default.
• W2990763313 hasConceptScore W2990763313C2776042228 @default.
• W2990763313 hasConceptScore W2990763313C2777037409 @default.
• W2990763313 hasConceptScore W2990763313C2777832160 @default.
• W2990763313 hasConceptScore W2990763313C2779758542 @default.
• W2990763313 hasConceptScore W2990763313C71924100 @default.
• W2990763313 hasLocation W29907633131 @default.
• W2990763313 hasOpenAccess W2990763313 @default.
• W2990763313 hasPrimaryLocation W29907633131 @default.
• W2990763313 hasRelatedWork W1989963822 @default.
• W2990763313 hasRelatedWork W2053208368 @default.
• W2990763313 hasRelatedWork W2076877981 @default.
• W2990763313 hasRelatedWork W2130602665 @default.
• W2990763313 hasRelatedWork W2216267862 @default.
• W2990763313 hasRelatedWork W2795422872 @default.
• W2990763313 hasRelatedWork W2922028923 @default.
• W2990763313 hasRelatedWork W2984320541 @default.
• W2990763313 hasRelatedWork W2995082828 @default.
• W2990763313 hasRelatedWork W4295899646 @default.
• W2990763313 isParatext "false" @default.
• W2990763313 isRetracted "false" @default.
• W2990763313 magId "2990763313" @default.
• W2990763313 workType "article" @default.